HER2-Negative Breast Cancer
FDA grants Breakthrough Therapy designation for ribociclib as an initial endocrine-based therapy for HR+/HER2- breast cancer in premenopausal or perimenopausal women.
Patients with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer who have a recurrence score of 11 to 25 may not benefit from chemotherapy.
Interim joint analysis of the ABC Trials showed invasive disease-free survival was significant for superiority of anthracycline/taxane-based chemotherapy regimens (TaxAC) relative to docetaxel plus cyclophosphamide, according to study results presented at the 2016 ASCO Annual Meeting.
The experimental drug nintedanib, in combination with standard paclitaxel chemotherapy, caused a total remission of tumors in half of patients with early stage HER2-negative breast cancer.
Evidence-based recommendations have been developed for chemotherapy and targeted therapy for women with HER2-negative advanced breast cancer.
A test of tumor microenvironment of metastasis (TMEM) predicted risk of distant metastasis in estrogen receptor-positive and HER2-negative breast cancer, according to a new study.
High intake of saturated fat increases risk of HER2-negative, ER/PR-positive disease.
Adding dasatinib to the standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer. These results of a phase 2 clinical trial were presented at the 2013 San Antonio Breast Cancer Symposium.
Adding the antibody therapy ramucirumab to docetaxel therapy did not delay disease progression for patients with HER2-negative, advanced breast cancer. These results, from a placebo-controlled, randomized, phase 3 clinical trial, were presented at the 2013 San Antonio Breast Cancer Symposium.
I-SPY 2 has yielded positive results with the first drug to complete testing during the trial. Adding carboplatin and veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results presented at the 2013 San Antonio Breast Cancer Symposium.
All persons with invasive breast cancer (early stage or recurrence) should undergo testing for human epidermal growth factor receptor 2 (HER2), and at least one tumor sample should be tested for either HER2 protein expression or HER2 gene amplification.
The monoclonal antibody trastuzumab (Herceptin) may be effective against HER2-negative breast cancers in addition to HER2-positive disease.
The protein HER2 plays a role even in breast cancers that would traditionally be categorized as HER2-negative. The drug trastuzumab (Herceptin), which targets HER2, may have an even greater role for treating breast cancer and preventing its spread.
The definition of hormone-sensitive breast tumors known as luminals has been changed by a recent study.
A drug used for metastatic breast cancer after several previous treatments may improve survival when administered earlier in the disease course.
Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.
Combining a PI3K inhibitor with a PARP inhibitor may be an effective therapy for triple-negative breast cancer, researchers have determined.
Overweight and obese women with hormone receptor (HR)-positive operable breast cancer have an increased risk of disease recurrence and death.
Metformin, prescribed to help control blood glucose levels in type 2 diabetes, may play a role in the prevention or management of breast cancer.
New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.
Positron emission tomography (PET) can help pinpoint a breast cancer diagnosis and predict prognosis in an aggressive form of the disease.
Two studies show improved pathologic complete response with addition of bevacizumab.
The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
This patient fact sheet provides questions you may want to ask your doctor about the results of your diagnostic tests and explains the significance of the answers to the questions.
The Oncologic Drug Advisory Committee recommended that the FDA withdraw its approval of bevacizumab's indication for breast cancer.
Sign Up for Free e-newsletters
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- When There Are No Words: Interpreting Patients' and Families' Subtle Messages
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|